[1] 陈万青, 李贺, 孙可欣, 等.  2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2018, 40(1): 5-13.   doi: 10.3760/cma.j.issn.0253-3766.2018.01.002
Chen WQ, Li H, Sun KX, et al.  Report of Cancer Incidence and Mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1): 5-13.   doi: 10.3760/cma.j.issn.0253-3766.2018.01.002
[2] Heston TF, Wahl RL.  Molecular imaging in thyroid cancer[J]. Cancer Imaging, 2010, 10(1): 1-7.   doi: 10.1102/1470-7330.2010.0002
[3] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I therapy of differentiated thyroid cancer (2014)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[4] 吉倩婧, 底瑞青, 陈伟娜, 等.  机器人用于分化型甲状腺癌术后131 I治疗住院患者体内残留放射性活度测定的研究[J]. 中华核医学与分子影像杂志, 2019, 39(10): 601-605.   doi: 10.3760/cma.j.issn.2095-2848.2019.10.006
Ji QJ, Di RQ, Chen WN, et al.  Measurement of residual radioactivity in postoperative inpatients with differentiated thyroid carcinoma after 131 I treatment using robot[J]. Chin J Nucl Med Mol Imaging, 2019, 39(10): 601-605.   doi: 10.3760/cma.j.issn.2095-2848.2019.10.006
[5] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[6]

中华人民共和国国家卫生和计划生育委员会. WS 533-2017临床核医学患者防护要求[S]. 北京: 中国标准出版社, 2017.

The State Health and Family Planning Commission of the People's Republic of China. WS 533-2017 Requirements for patient radiation protection in nuclear medicine[S]. Beijing: Standards Press of China, 2017.
[7] Kogai T, Brent GA.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics[J]. Pharmacol Ther, 2012, 135(3): 355-370.   doi: 10.1016/j.pharmthera.2012.06.007
[8] Bartlett ML.  Estimated dose from diagnostic nuclear medicine patients to people outside the Nuclear Medicine department[J]. Radiat Prot Dosimetry, 2013, 157(1): 44-52.   doi: 10.1093/rpd/nct119
[9]

汤敏敏, 刘建中, 武志芳, 等. 分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J]. 中华放射医学与防护杂志, 2015, 35(4): 299-302. DOI: 10.3760/cma.j.issn.0254−5098.2015.04.016.

Tang MM, Liu JZ, Wu ZF, et al. Estimation of residual activity in patients with differentiated thyroid cancer after administration of 131I for therapy[J].Chin J Radiol Med Prot, 2015, 35(4): 299-302. DOI: 10.3760/cma.j.issn.0254−5098.2015.04.016.
[10] 袁海娟, 林主戈, 吴春兴, 等.  131I治疗分化型甲状腺癌患者体内残留辐射剂量及病房辐射剂量的监测分析[J]. 国际放射医学核医学杂志, 2019, 43(5): 400-404.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.003
Yuan HJ, Lin ZG, Wu CX, et al.  Radiation monitoring in patients with differentiated thyroid carcinoma treated with iodine-131 and their wards[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 400-404.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.003
[11] 康增寿, 李方, 林岩松.  开放性放射性核素治疗后患者免住院的建议(ICRP94报告要点解读)[J]. 国际放射医学核医学杂志, 2019, 43(5): 397-399.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.002
Kang ZS, Li F, Lin YS.  Release of patients therapy with unsealed radionuclides (ICRP publication 94)[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 397-399.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.002
[12] Wang B, Katsube T, Begum N, et al.  Revisiting the health effects of psychological stress-its influence on susceptibility to ionizing radiation: a mini-review[J]. J Radiat Res, 2016, 57(4): 325-335.   doi: 10.1093/jrr/rrw035
[13] Rosenthal MS.  Patient Misconceptions and ethical challenges in radioactive iodine scanning and therapy[J]. J Nucl Med Technol, 2006, 34(3): 143-150.
[14] 史文杰, 汪小龙, 王月英.  浅谈放射性核素治疗病房的建设与管理[J]. 国际放射医学核医学杂志, 2019, 43(5): 411-415.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.005
Shi WJ, Wang XL, Wang YY.  Building and management of the radionuclide treatment ward[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 411-415.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.005